Szczylik, C
78  results:
Search for persons X
?
3

Final results from the large sunitinib global expanded-acce..:

Gore, M E ; Szczylik, C ; Porta, C...
British Journal of Cancer.  113 (2015)  1 - p. 12-19 , 2015
 
?
4

Assessing the impact of evolving evidence in renal cell car..:

Gore, M.E. ; Bellmunt, J. ; Eisen, T....
European Journal of Cancer.  50 (2014)  18 - p. 3153-3160 , 2014
 
?
5

Insights into cancer surveillance inCentral andEasternEurop..:

Vrdoljak, E. ; Torday, L. ; Sella, A....
European Journal of Cancer Care.  24 (2013)  1 - p. 99-110 , 2013
 
?
6

O4 Tivozanib hydrochloride versus sorafenib as initial targ..:

Motzer, R. ; Nosov, D. ; Eisen, T....
European Urology Supplements.  11 (2012)  5 - p. 185 , 2012
 
?
7

Evaluation of treatment options for patients with advanced ..:

Gore, M.E. ; Bellmunt, J. ; Eisen, T....
European Journal of Cancer.  48 (2012)  7 - p. 1038-1047 , 2012
 
?
 
?
 
?
 
?
11

7114 POSTER DISCUSSION Appropriateness of Treatment Options..:

Gore, M. ; Bellmunt, J. ; Eisen, T....
European Journal of Cancer.  47 (2011)  - p. S508-S509 , 2011
 
?
12

Oral treatment of metastatic breast cancer with capecitabin..:

GÓRNAŚ, M. ; SZCZYLIK, C.
European Journal of Cancer Care.  19 (2010)  1 - p. 131-136 , 2010
 
?
 
?
14

17LBA TRIST: A randomised, double blind, placebo controlled..:

Hawkins, R. ; Harrop, R. ; Naylor, S....
European Journal of Cancer Supplements.  7 (2009)  3 - p. 11 , 2009
 
?
 
1-15